Acute Myeloid Leukemia Presenting as “Bowel Upset”: A Case Report

SMEETA GAJENDRA1, AJAY GOGIA2, PRASENJIT DAS3, RITU GUPTA4, PRANAY TANWAR5

ABSTRACT
Myeloid sarcomas (MS) are the extramedullary presentation of acute myeloid leukemias. At times, they are difficult to diagnose due to lack of any supportive findings in peripheral blood/bone marrow aspirate examination. The involvement of gastrointestinal tract (GIT) by myeloid sarcoma is rare phenomenon. This diagnostic challenge becomes more complex when it is added by vague clinical symptoms. Many times, they have been misdiagnosed as Non-Hodgkin’s lymphoma, small round cell tumour or carcinoma. Here, we are reporting a case of myeloid sarcoma with no haematological abnormality which presented with the symptoms of bowel obstruction and a rare combination of inv. (16) and trisomy 22. The journey to reach the conclusive diagnosis in this case is interesting and sensitizes us to have high index of suspicion in a case, where there is paucity of clinical evidences.

CASE REPORT
A 35-year-old male presented with repeated episodes of abdominal pain, distension, vomiting and constipation for 3 months. The patient was afebrile with abdominal tenderness and distension without any lymphadenopathy or organomegaly. The patient was evaluated outside of our institution for intestinal obstruction. Ultrasonography showed bilateral pleural effusion with gross ascites and ileo-ileal intussusception. Laboratory examinations including complete blood count, liver and renal function test were within normal limit. On laparotomy, there was adhesion between small bowel loops due to hard intraluminal constricting mass 3x3 cm which was 15cm away from duodenoejejunal flexure. Another mass of 5x5 cm was located around 7.5cm proximal to ileoceleal junction and the third ill-defined mass was at ileoceleal junction involving appendix, caecum, terminal ileum and ascending colon. Excision of proximal jejunal mass with jejuno-jejunal anastomosis and ileostomy was done. Excisional biopsy of mass showed monotonous medium sized tumour cell population, resembling lymphoid cell morphology, which were positive for CD45, CD3 and negative for CD19,CD10,CD20,CD5 and CD30, suggesting a diagnosis of T-cell lymphoma. No further action was taken and patient wanted to consult in our institute. After one month patient was presented to our hospital with fatigue and weakness. On examination, he had pallor without any lymphadenopathy or organomegaly. CT scan of abdomen showed circumferential jejunal wall thickening with conglomerate mesentric nodal mass and retroperitoneal adenopathy. The haemoglobin was 90g/L, total leucocyte count was 5.6x10^9/L and platelet count was 102x10^9/L. PBS and BMA showed 40% and 80% myeloperoxidase (MPO) positive blasts with many showing auer rods, respectively [Table/Fig-1a]. On flowcytometric immunophenotyping, blasts were positive for CD45, CD34, HLA-DR, cMPO, CD117, CD13, CD33 and CD64; and negative for cCD79a, CD3, CD19 and CD14. The excisional biopsy of small intestine was reviewed in our institution which revealed small intestinal mucosa infiltrated by atypical cells [Table/Fig-1b] with moderate eosinophilic cytoplasm which were destroying the mucosal glands and infiltrating into periserosal fat. On immunohistochemistry (IHC), these atypical cells were immunopositive for CD34 and MPO [Table/Fig-1c,d] and negative for CD19, CD20, CD79a, CD3, CD4, CD8, CD6, CD138 and CD30. CG showed inv (16) (p13q22) and trisomy 22. A final diagnosis of acute myeloid leukemia with inv (16) and trisomy 22, preceded by granulocytic sarcoma of small jejenum was made. The patient was started on 3+7 induction chemotherapy and post induction the bone marrow was in morphological remission.

DISCUSSION
Granulocytic sarcoma/myeloid sarcoma (MS) is an uncommon tumour composed of myeloid blasts and/or immature myeloid cells at an extramedullary site. MS may occur as an isolated leukenic tumour or precede the appearance of blood or bone marrow disease or may present concurrently with /at relapse of acute myeloid leukemia (AML). It can occur at any anatomical site, most common sites being the skin (13%–22%), bone/spine (9%–25%), and lymph nodes (15%–25%) [1]. Involvement of gastrointestinal tract is rare with the commonest site being ileum (10%–11%) followed by stomach and large intestine [2]. In cases of involvement of gastrointestinal tract (GIT), diagnosis is often delayed due to wide spectrum of vague signs and symptoms such as intermittent abdominal pain, diarrhoea, fever, nausea, vomiting and weight loss [3]. These patients may present with GIT bleeding, perforation or obstruction. The histopathological diagnosis of MS can be challenging, especially if there are paucity of supportive findings in peripheral blood/bone marrow aspirate examination. The involvement of gastrointestinal tract (GIT) by myeloid sarcoma is rare. This diagnostic challenge becomes more complex when it is added by vague clinical symptoms. Many times, they have been misdiagnosed as Non-Hodgkin’s lymphoma, small round cell tumour or carcinoma. Here, we are reporting a case of myeloid sarcoma with no haematological abnormality which presented with the symptoms of bowel obstruction and a rare combination of inv. (16) and trisomy 22. The journey to reach the conclusive diagnosis in this case is interesting and sensitizes us to have high index of suspicion in a case, where there is paucity of clinical evidences.

Keywords: Acute myeloid leukemia, Blast, Intussusception, Myeloid sarcomas, Lymphadenopathy
MS involving small intestine presenting as intussusception is rare, the histopathological diagnosis may be challenging initially, especially in the setting of normal haematological parameters. Hence high index of clinical suspicion is required to reach the conclusive opinion, so as to minimize the time lag between diagnosis and management.

ACKNOWLEDGEMENT

Dr. Uma Kumar, Senior Resident, Laboratory Oncology Unit, IRCH, AIIMS, New Delhi, India.

REFERENCES


CONCLUSION

when there is no evidence of any neoplastic haematological disorder. It is frequently mistaken for Non-Hodgkin lymphoma (NHL), small round cell tumour or undifferentiated carcinoma. The diagnosis can be facilitated by multiple modalities such as immunoperoxidase stains, immunohistochemistry, conventional cytogenetics (CG), and flow cytometry [2]. Few cases of AML having inv. (16) and other cytogenetic anomalies presenting with MS of GIT have been reported in medical literature previously [Table/Fig-2] [4-7]. It is evident with the literature search that myeloid sarcoma is not so common phenomenon. The combination of cytogenetic anomaly is still rarer. Though, the implication of cytogenetic anomaly on the presenting feature have not been correlated yet, still some of them have been compiled in [Table/Fig-2]. In the absence of abnormal haematological parameters, histopathological diagnosis of MS is challenging and 47%–56% of patients may be diagnosed as other conditions, most commonly NHL [2]. One of the case [8], of MS in nasopharynx, which was reported as NHL, was reviewed after 8months, when patient had persistent thrombocytopenia. Here in this case too, an initial diagnosis of T-cell NHL was made due to rare clinical presentation as intussusception and normal haematological parameter. The CG of this case, revealed inv. (16) along with trisomy 22. This combination of cytogenetic anomaly is rare and has never been reported in medical literature till date. Only one case [9], of MS of breast having trisomy 22 alone has been cited. The treatment options of myeloid sarcoma of gastrointestinal involve remain the same as that of AML that is, systemic chemotherapy with bone marrow transplantation in addition to surgical resection in appropriate clinical settings. One of the study [10], has concluded, that MS is associated with superior event-free survival and overall survival compared with AML based on the evaluation done on same anti-AML therapy.

TABLE/Figure-2: Cases of myeloid sarcoma with AML subtype and associated cytogenetics

<table>
<thead>
<tr>
<th>Authors</th>
<th>FAB Classification</th>
<th>Cytogenetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Le Beau et al., [4], 1983</td>
<td>AML-M4</td>
<td>inv(16)</td>
</tr>
<tr>
<td>Russell et al., [5], 1988</td>
<td>AML-M4</td>
<td>50,XY,+6,+9,+14,inv(16),+22</td>
</tr>
<tr>
<td>Morel et al., [6], 2002</td>
<td>AML-M2</td>
<td>inv(16), trisomy 9 and 22</td>
</tr>
<tr>
<td>Alvarez et al., [7], 2011</td>
<td>AML-M2</td>
<td>CBFβ/MYH11, inv(16)</td>
</tr>
<tr>
<td>Present case</td>
<td>AML-M2</td>
<td>inv(16), trisomy 22</td>
</tr>
</tbody>
</table>

FINANCIAL OR OTHER COMPETING INTERESTS: None.

PARTICULARS OF CONTRIBUTORS:
1. Attending Consultant, Department of Pathology and Laboratory Medicine, Medanta Hospital, Gurgoan, Haryana, India.
2. Assistant Professor, Department of Medical Oncology, Dr BR Ambedkar Institute of Medical Sciences, New Delhi, India.
3. Assistant Professor, Department of Pathology, AIIMS, New Delhi, India.
4. Additional Professor, Laboratory Oncology Unit, Dr BR Ambedkar Institute of Medical Sciences, New Delhi, India.
5. Assistant Professor, Laboratory Oncology Unit, Dr BR Ambedkar Institute of Medical Sciences, New Delhi, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Pranay Tanwar,
Room No. 425, 4th Floor, IRCH, AIIMS, New Delhi-110029, India.
Phone: 9968722016, E-mail: pranaytanwar@gmail.com, pranaytanwar@aiims.ac.in

Date of Submission: Mar 02, 2014
Date of Peer Review: May 22, 2014
Date of Acceptance: May 28, 2014
Date of Publishing: Jul 20, 2014